About Biohaven Pharmaceutical
Biohaven Pharmaceutical is a company based in New Haven (United States) founded in 2014 was acquired by Pfizer in May 2022. Biohaven Pharmaceutical has raised $84.1 million across 3 funding rounds from investors including Pfizer, RA Capital and Portage Biotech. Biohaven Pharmaceutical has completed 3 acquisitions, including Channel Bio-Sciences, Kleo Pharmaceuticals and Priorityreviewvoucher. Biohaven Pharmaceutical offers products and services including Nurtec ODT and Zavzpret. Biohaven Pharmaceutical operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter New Haven, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biohaven Pharmaceuticals Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$84.1 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Pfizer
& 10 more
-
Employee Count
Not available
-
Investments & Acquisitions
Channel Bio-Sciences
& 2 more
-
Acquired by
Pfizer
(May 10, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biohaven Pharmaceutical
Biohaven Pharmaceutical is a publicly listed company on the NYSE with ticker symbol BHVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biohaven Pharmaceutical
Biohaven Pharmaceutical offers a comprehensive portfolio of products and services, including Nurtec ODT and Zavzpret.
Oral dissolving tablet for migraine treatment and relief.
Nasal spray option for effective migraine management.
People of Biohaven Pharmaceutical
Unlock access to complete
Unlock access to complete
Funding Insights of Biohaven Pharmaceutical
Biohaven Pharmaceutical has successfully raised a total of $84.1M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biohaven Pharmaceutical
Biohaven Pharmaceutical has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, RA Capital and Portage Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked |
Investor details for Biohaven Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biohaven Pharmaceutical
Biohaven Pharmaceutical has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Channel Bio-Sciences, Kleo Pharmaceuticals and Priorityreviewvoucher.
Investment portfolio details for Biohaven Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Healthcare consulting services are provided to industry clients.
|
Locked | Locked | 2016 | Locked | |
|
Developing a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and infectious diseases
|
Locked | Locked | 2015 | Locked | |
|
Priority review vouchers are supplied for expedited drug approvals.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Biohaven Pharmaceutical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biohaven Pharmaceutical
Detailed financials for Biohaven Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biohaven Pharmaceutical Comparisons
Peer comparison for Biohaven Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biohaven Pharmaceutical
Biohaven Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Biohaven Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biohaven Pharmaceutical
Complete news archive for Biohaven Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biohaven Pharmaceutical
Biohaven Pharmaceutical was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Biohaven Pharmaceutical is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Biohaven Pharmaceutical is a funded company, having raised a total of $84.1M across 3 funding rounds to date.
Biohaven Pharmaceutical was founded in 2014 in New Haven, United States, within the biotechnology sector. Therapies targeting neurological and neuropsychiatric conditions are developed by the company. The pipeline includes BHV-0223, a glutamate-modulating agent under FDA review, along with BHV-4157 for spinocerebellar ataxia treatment and SHV-5000i, an NMDA receptor antagonist for post-traumatic stress disorder and treatment-resistant depression. Operations focus on drug development for these areas.
Biohaven Pharmaceutical's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and PureTech Health.
Biohaven Pharmaceutical offers Nurtec ODT and Zavzpret.
Yes, Biohaven Pharmaceutical is publicly traded on NYSE under the ticker symbol BHVN.
Biohaven Pharmaceutical has made 3 acquisitions, including Channel Bio-Sciences, Kleo Pharmaceuticals, and Priorityreviewvoucher.
Biohaven Pharmaceutical has 11 investors. Key investors include Pfizer, RA Capital, Portage Biotech, Venrock, and Aisling Capital.
The ticker symbol of Biohaven Pharmaceutical is BHVN on NYSE.